Table 1.
Anthropometric and clinical characteristics, lipid profile, and inflammatory markers.
| NTG Group (n = 13) | HTG Group (n = 12) | Control Group (n = 15) | |||
|---|---|---|---|---|---|
| Age (years) | 48.6 ± 10.6 | 51.1 ± 6.6 | 48.4 ± 6.0 | ||
| Gender (M/F) | 7/5 | 8/4 | 9/6 | ||
| Baseline | After Therapy | Baseline | After Therapy | ||
| BMI (kg/m2) | 27.1 ± 4.3 | 26.5 ± 4.4 | 27.1 ± 4.7 | 27.3 ± 4.6 | 24.7 ± 4.3 |
| Cholesterol (mmol/L) | 7.18 ± 0.89 | 4.71 ± 0.66 * | 7.44 ± 0.81 | 5.04 ± 0.91 * | 5.44 ± 0.99 a,c |
| Triglycerides (mmol/L) | 1.84 ± 0.44 | 1.40 ± 0.54 * | 3.61 ± 0.79 a | 2.35 ± 0.73 *,a,b | 0.93 ± 0.28 a,c,d |
| VLDL-c (mmol/L) | 0.87 ± 0.20 | 0.59 ± 0.20 * | 1.51 ± 0.47 a | 1.02 ± 0.25 *,a,b | 0.43 ± 0.13 a,c,d |
| LDL-c (mmol/L) | 5.02 ± 0.78 | 2.73 ± 0.54 * | 4.95 ± 0.75 | 3.03 ± 0.89 * | 3.31 ± 0.96 a,c |
| HDL-c (mmol/L) | 1.29 ± 0.37 | 1.28 ± 0.35 | 0.98 ± 0.14 a | 0.99 ± 0.22 a,b | 1.51 ± 0.19 c,d |
| ApoB (mmol/L) | 1.50 ± 0.19 | 0.90 ± 0.16 * | 1.64 ± 0.19 | 1.11 ± 0.22 * | 0.95 ± 0.18 a,c |
| CRP (mg/L) | 2.79 ± 2.45 | 1.72 ± 1.64 * | 2.73 ± 2.51 | 1.56 ± 1.30 * | 1.02 ± 0.63 a,c |
| Leptin (µg/L) | 36.3 ± 30.3 | 43.9 ± 32.3 | 28.6 ± 33.7 | 29.5 ± 30,0 | 33.6 ± 29.7 |
| Adiponectin (µg/L) | 10.9 ± 2.5 | 11.1 ± 2.7 | 10.2 ± 2.1 | 10.3 ± 1.7 | 10.2 ± 2.4 |
* p < 0.05 vs. basal samples. a p < 0.05 vs. basal NTG. b p < 0.05 vs. NTG post-treatment. c p < 0.05 vs. basal HTG. d p < 0.05 vs. HTG post-treatment.